Nutex Health (NUTX) CLO acquires shares and corrects RSU holdings

Rhea-AI Filing Summary

Nutex Health Inc. Chief Legal Officer-Healthcare Pamela W. Montgomery reported acquiring additional equity in the company. She made an open-market purchase of 79 shares of common stock at a price of $88.8699 per share, bringing her directly held common stock position to 2,758 shares.

She also exercised a derivative position in the form of 1,523 restricted stock units, converting them into an equivalent common stock interest at a stated exercise price of $0.00, with 4,441 restricted stock units beneficially owned following this transaction. A footnote explains that this filing corrects the previously reported number of restricted stock units from an earlier Form 4 relating to the March 10, 2026 RSU grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Montgomery Pamela W.

(Last) (First) (Middle)

1776 YORKTOWN STREET

SUITE 700

(Street)

HOUSTON TX 77056

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nutex Health Inc. [ NUTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer-Healthcare

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		P		79	A	$88.8699	2,758	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit(1)	$0	03/10/2026		M		1,523		03/01/2027	03/01/2029	Common Stock	1.523(1)	$0	4,441	D

Explanation of Responses:

1. This Form 4 corrects the number of restricted stock units (RSUs) beneficially owned following the RSU grant reported in the reporting person's Form 4 filed on March 10, 2026 relating to a transaction dated March 10, 2026.

	/s/ Pamela Montgomery	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Nutex Health (NUTX) report for Pamela W. Montgomery?

Pamela W. Montgomery reported two acquisition-side transactions. She bought 79 shares of Nutex Health common stock in the open market and exercised 1,523 restricted stock units, increasing both her direct shareholdings and her restricted stock unit position in the company.

How many Nutex Health (NUTX) common shares does Pamela W. Montgomery hold after these transactions?

After the reported open-market purchase, she holds 2,758 common shares directly. This figure reflects her position following the acquisition of 79 additional shares at $88.8699 per share, as disclosed in the Form 4 for the March 13, 2026 transaction.

What happened with Pamela W. Montgomery’s restricted stock units in Nutex Health (NUTX)?

She exercised 1,523 restricted stock units tied to Nutex Health common stock. Following this derivative exercise, the filing states she beneficially owns 4,441 restricted stock units, and clarifies that this Form 4 corrects the previously reported RSU balance from an earlier filing.

Was Pamela W. Montgomery’s Nutex Health (NUTX) Form 4 a correction?

Yes, the Form 4 includes a corrective element. A footnote states that it corrects the number of restricted stock units beneficially owned after the RSU grant reported in her earlier Form 4 filed on March 10, 2026, for a March 10, 2026 transaction.

Did Pamela W. Montgomery sell any Nutex Health (NUTX) shares in this Form 4?

No sales are reported in this Form 4. The filing shows an open-market purchase of 79 common shares and the exercise of 1,523 restricted stock units, with no dispositions, gifts, or tax-withholding transactions disclosed for these dates.

What prices are associated with Pamela W. Montgomery’s Nutex Health (NUTX) transactions?

The open-market purchase was at $88.8699 per common share. The derivative transaction involved exercising 1,523 restricted stock units at an exercise price of $0.00 per unit, converting them into an equivalent interest in Nutex Health common stock.